Radioactive Iodine in Intermediate-Risk Differentiated Thyroid Cancer: Bridging Evidence Gaps with Patient Decision Aids

Abstract

Get full access to this article

View all access options for this article.

References

1. Ringel

, Sosa

, Baloch

, et al. 2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 2025;35(8):841-985; doi: 10.1177/10507256251363120.

2. Carr

, Gabriel

, Pillai

, et al. Patient perspectives toward a decision aid for radioactive iodine treatment for intermediate risk thyroid cancer. Int J Behav Med. Epub 2025; doi: 10.1007/s12529-025-10408-4.

3. Ruel

, Thomas

, Dinan

, et al. Adjuvant radioactive iodine and survival in intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab 2015;100(4):1529-1536; doi: 10.1210/jc.2014-4332.

4. Sawka

, Straus

, Rotstein

, et al. Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer. J Clin Oncol 2012;30(23):2906-2911; doi: 10.1200/JCO.2011.41.2734.

5. Karcioglu

, Dhillon

, Davies

, et al. Analysis of unmet information needs among patients with thyroid cancer. JAMA Otolaryngol Head Neck Surg 2023;149(2):110-119; doi: 10.1001/jamaoto.2022.4108.

6. Lee

, Kim

, Hwangbo

, et al. Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer: Protocol of a Multicenter Cluster-Randomized Trial (MAeSTro-SDM). J Korean Med Sci 2026;41(4):e58; doi: 10.3346/jkms.2026.41.e58.